OPTIRAY
Drug
GUERBET LLC
Total Payments
$54,787
Transactions
1
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $54,787 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $54,787 | 1 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Feasibility, efficacy and safety of a Zero Acute Kidney Injury (Zero-AKI) Strategy for percutaneous coronary intervention in patients with chronic kidney disease | GUERBET LLC | $54,787 | 0 |
Top Doctors Receiving Payments for OPTIRAY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Richmond, VA | $54,787 | 1 |
Ad
Manufacturing Companies
- GUERBET LLC $54,787
Product Information
- Type Drug
- Total Payments $54,787
- Total Doctors 0
- Transactions 1
About OPTIRAY
OPTIRAY is a drug associated with $54,787 in payments to 0 healthcare providers, recorded across 1 transactions in the CMS Open Payments database. The primary manufacturer is GUERBET LLC.
Payment data is available from 2021 to 2021. In 2021, $54,787 was paid across 1 transactions to 0 doctors.
The most common payment nature for OPTIRAY is "Unspecified" ($54,787, 100.0% of total).
OPTIRAY is associated with 1 research study, including "Feasibility, efficacy and safety of a Zero Acute Kidney Injury (Zero-AKI) Strategy for percutaneous coronary intervention in patients with chronic kidney disease" ($54,787).